CALL US AT: (949) 396-0330
CONNECT WITH NEMUS BIOSCIENCE INC.:

NEMUS Bioscience, Inc.

NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids.

About Us

NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS Bioscience Inc. is developing novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS.

VISION

To offer physicians and patients the medical benefits of "condition-specific" cannabinoids to alleviate symptoms associated with a range of diseases.

MISSION

The Nemus Bioscience mission is to become the leading developer of regulatory-approved cannabinoid-based therapeutics utilizing world-class proprietary bioengineering coupled to innovative biosynthetic manufacturing, to address large market unmet medical needs on a global scale in a strategic, legal and cost-effective manner. Our incubator model is designed to monetize our pharmaceuticalized cannabinoids during optimal stages of drug development to maximize shareholder value.

WHY NEMUS Bioscience Inc.

  • NEMUS brings proprietary bioengineering to cannabinoid-based therapeutics to optimize therapeutic targeting
  • NEMUS is currently the only partner of the University of Mississippi for the development and commercialization of these bioengineered cannabinoid-based drug candidates.
  • The University of Mississippi is currently the only US entity authorized by the Federal government for the past 49 years to cultivate and study cannabis resulting in significant intellectual capital
  • NEMUS is currently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment of ocular diseases like glaucoma
  • NEMUS is currently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment and management of infectious diseases
  • NEMUS is currently the only cannabinoid drug developer utilizing biosynthetic approaches for the manufacturing of Nemus drug products

Our Partners

  • Logo
  • Logo
  • Logo

  • Logo
  • Logo
  • Logo

  • Logo
  • Logo